Iron metabolism and ferroptosis in nonalcoholic fatty liver disease: what is our next step?

被引:3
|
作者
Shen, Xiang [1 ]
Yu, Ziqi [1 ]
Wei, Changli [2 ]
Hu, Chong [2 ]
Chen, Jianyong [2 ]
机构
[1] Ludwig Maximilian Univ Munich, Munich Med Res Sch, Munich, Germany
[2] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Dept Obstet & Reprod Hlth, Nanchang, Peoples R China
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2024年 / 326卷 / 06期
基金
中国国家自然科学基金;
关键词
ferroptosis; iron metabolism; lipid peroxidation; NAFLD; NASH; INSULIN-RESISTANCE; HOMEOSTASIS; ACTIVATION; FIBROSIS; PROGRESSION; EXPRESSION; PHLEBOTOMY; AUTOPHAGY; DEPLETION; HEPCIDIN;
D O I
10.1152/ajpendo.00260.2023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increasing prevalence worldwide. NAFLD could develop from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), NASH-related fibrosis, cirrhosis, and even hepatocellular carcinoma. However, the mechanism of NAFLD development has not yet been fully defined. Recently, emerging evidence shows that the dysregulated iron metabolism marked by elevated serum ferritin, and ferroptosis are involved in the NAFLD. Understanding iron metabolism and ferroptosis can shed light on the mechanisms of NAFLD development. Here, we summarized studies on iron metabolism and the ferroptosis process involved in NAFLD development to highlight potential medications and therapies for treating NAFLD.
引用
收藏
页码:E767 / E775
页数:9
相关论文
共 50 条
  • [21] Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?
    Moris, Wenke
    Verhaegh, Pauline
    Jonkers, Daisy
    van Deursen, Cees
    Koek, Ger
    SEMINARS IN LIVER DISEASE, 2019, 39 (04) : 476 - 482
  • [22] Personalizing care for nonalcoholic fatty liver disease patients: what are the research priorities?
    Sookoian, Silvia
    Pirola, Carlos J.
    PERSONALIZED MEDICINE, 2014, 11 (08) : 735 - 743
  • [23] Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
    Bhat, Neha
    Mani, Arya
    NUTRIENTS, 2023, 15 (10)
  • [24] Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Hung, Chun Kit
    Bodenheimer, Henry C., Jr.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 175 - +
  • [25] Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Imajo, Kento
    Yoneda, Masato
    Kessoku, Takaomi
    Ogawa, Yuji
    Maeda, Shin
    Sumida, Yoshio
    Hyogo, Hideyuki
    Eguchi, Yuichiro
    Wada, Koichiro
    Nakajima, Atsushi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (11) : 21833 - 21857
  • [26] Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Golabi, Pegah
    Bush, Haley
    Younossi, Zobair M.
    CLINICS IN LIVER DISEASE, 2017, 21 (04) : 739 - 753
  • [27] Visceral adipose tissue visfatin in nonalcoholic fatty liver disease
    Gaddipati, Radhika
    Mitnala, Sasikala
    Padaki, Nagarajarao
    Mukherjee, Rathindra Mohan
    Sekaran, Anuradha
    Jayaraj-Mansard, Magnus
    Rabella, Pradeep
    Rao-Guduru, Venkat
    Reddy-Duvvuru, Nageshwar
    ANNALS OF HEPATOLOGY, 2010, 9 (03) : 266 - 270
  • [28] Porphyromonas gingivalis is a risk factor for the development of nonalcoholic fatty liver disease via ferroptosis
    Yao, Chao
    Lan, Dongmei
    Li, Xue
    Wang, Yan
    Qi, Shengcai
    Liu, Yuehua
    MICROBES AND INFECTION, 2023, 25 (1-2)
  • [29] Nonalcoholic fatty liver disease
    Erickson, Sandra K.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S412 - S416
  • [30] Iron Metabolism and Ferroptosis in Diabetic Kidney Disease
    Mu, Fangxin
    Luo, Ping
    Zhu, Yuexin
    Nie, Ping
    Li, Bing
    Bai, Xue
    CELL BIOCHEMISTRY AND FUNCTION, 2025, 43 (04)